Browse studies

Find your next paid study

1,252 recruiting studies matching your filters

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary…

Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+8 more

A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors

The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tum…

Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more

Estimated

~$10 – $8,750

Phase 3

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLC+2 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT06881784

Phase 1

A Phase 1 Study of IM-1617 in Participants With Advanced Malignancies

This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that ha…

Colorectal CancerNon-Small Cell Lung CancerBreast Cancer+3 more

Estimated

~$10 – $8,750

Immunome, Inc.NCT07578571

Phase 2

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small r…

Desmoplastic Small Round Cell TumorOsteosarcomaRecurrent Desmoplastic Small Round Cell Tumor+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04616560

Phase 2

A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients With Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to…

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell Carcinoma+15 more

Estimated

Observational

Enhancing Stability and Connection: A Manualized Recreational Therapy Balance Program for Older Adults With Parkinson's and Movement Disorders in Oklahoma Small Cities

This study evaluates a manualized recreational therapy balance program for older adults with Parkinson's disease and movement disorders who live in small citie…

Parkinson Disease (PD), Postural BalanceMovement Disorders (Incl Parkinsonism)Postural Balance+1 more

Estimated

~$10 – $6,250

Oklahoma State UniversityNCT07845474

Phase 4

Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy

The goal of this clinical trial is to learn how quickly omalizumab begins to work in people with food allergy. The main question it aims to answer is: * Does …

Food Allergy

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07845552

Phase 1

An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP5…

Non-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal Carcinoma+5 more

Estimated

~$10 – $7,500

AstraZenecaNCT05877599

Phase 2

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, F…

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Estimated

~$10 – $8,750

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05128825

Phase 3

DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus s…

Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07472517

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the …

Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+4 more

Estimated

~$10 – $8,750

Accent TherapeuticsNCT06799065